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The olfactory bulb (OB) is the first processing station in the olfactory pathway.
Despite smell impairment, which is considered an early event in Alzheimer’s disease
(AD), little is known about the initial molecular disturbances that accompany the
AD development at olfactory level. We have interrogated the time-dependent OB
molecular landscape in Tg2576 AD mice prior to the appearance of neuropathological
amyloid plaques (2-, and 6-month-old), using combinatorial omics analysis. The
metabolic modulation induced by overproduction of human mutated amyloid precursor
protein (APP) clearly differs between both time points. Besides the progressive
perturbation of the APP interactome, functional network analysis unveiled an
inverse regulation of downstream extracellular signal-regulated kinase (ERK1/2), and
p38 mitogen-activated protein kinase (MAPK) routes in 2-month-old Tg2576 mice
with respect to wild-type (WT) mice. In contrast, Akt and MAPK kinase 4 (SEK1)/
stress-activated protein kinase (SAPK) axis were parallel activated in the OB
of 6-months-old-Tg2576 mice. Furthermore, a survival kinome profiling performed
during the aging process (2-, 6-, and 18-month-old) revealed that olfactory APP
overexpression leads to changes in the activation dynamics of protein kinase A (PKA),
Abbreviations: AD, Alzheimer’s disease; Akt, Protein kinase B; APP, Amyloid precursor protein; ATF2, Activating
Transcription Factor 2; CaMKII, Ca2+/calmodulin-dependent protein kinase II; ERK, Extracellular signal-regulated kinase;
FAK, Focal adhesion kinase; MEK, ERK Activator Kinase; OB, Olfactory bulb; p38 MAPK, p38 mitogen-activated protein
kinase; PDK1, Phosphoinositide-dependent protein kinase 1; Phb, Prohibitin; PKA, protein kinase A; PKC, protein
kinase C; PP5, Serine/threonine-protein phosphatase 5; SAPK/JNK, stress-activated protein kinase/Jun-amino terminal
kinase; SEK1/MKK4, Mitogen-activated protein kinase Kinase 4.
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and SEK1/MKK4-SAPK/JNK between 6 and 18 months of age, when memory deficits
appear and AD pathology is well established in transgenic mice. Interestingly, both
olfactory pathways were differentially activated in a stage-dependent manner in human
sporadic AD subjects with different neuropathological grading. Taken together, our
data reflect the early impact of mutated APP on the OB molecular homeostasis,
highlighting the progressive modulation of specific signaling pathways during the
olfactory amyloidogenic pathology.
Keywords: Alzheimer’s disease, olfactory bulb, network biology, proteomics, transcriptomics, Tg2576 mice
INTRODUCTION
Together with typical symptoms, such as memory loss and
behavioral disorders, Alzheimer’s disease (AD) patients present
olfactory dysfunction in 90% of the cases (Attems et al., 2014;
Daulatzai, 2015). However, the etiology of this smell impairment
is complex and remains mostly unknown. Neuropathological
studies support the hypothesis that hyperphosphorylated Tau
and Aβ aggregation, present in the olfactory bulb (OB), are
early and important events in the AD pathophysiology (Rey
et al., 2018). It has been demonstrated that these protein deposits
reflect the presence and severity of AD pathology in other brain
structures (Attems et al., 2014).
Although no animal model recapitulates the entirety of
human AD pathology (Sasaguri et al., 2017), some AD transgenic
mouse models also present olfactory deficits. Tg2576 transgenic
mice express an isoform of human amyloid precursor protein
(APP) with double mutation K670N, M671L (hAPPSw; Hsiao
et al., 1996). Production of Aβ40 and Aβ42 and plaques
formation are observed in cortical and hippocampal areas of
these mice at the age of 11–13 months (Puzzo et al., 2015).
Previous reports have pointed out that the accumulation of
Aβ peptide is related to age-related memory decline in these
mice (Chen et al., 2000; Janus et al., 2000; Westerman et al.,
2002), inducing synaptic deficits and mitochondrial imbalance
(Reddy et al., 2004; Jacobsen et al., 2006). The presence of
APP processing products has been characterized in the OB
of 1-month-old Tg2576 mice (Lehman et al., 2003). This
progressive Aβ deposition in specific olfactory structures is
accompanied by behavioral deficits in odor habituation and
discrimination, diminished rate of OB neurogenesis, and an
altered volume of the OB granular cell layer in Tg2576 mice
(Guérin et al., 2009; Young et al., 2009;Wesson et al., 2010, 2011).
Several studies using human AD brains and AD mouse
models have demonstrated that the deposition of amyloid
plaques is accompanied by an alteration in the OB’s molecular
homeostasis (Zelaya et al., 2015; Lachén-Montes et al., 2016,
2017; Palomino-Alonso et al., 2017). However, it is still unclear
how the progressive amyloidogenic pathology affects the OB
functionality in the absence of plaques. In this study, we have
used two high-throughput technological platforms, combining
transcriptomic and proteomic approaches to ascertain the
magnitude and chronology of the OB molecular remodeling in
Tg2576 mice at two stages of AD: long before (2 months of
age), and immediately before (6 months of age) the appearance
of Aβ plaques, with respect to age-matched background strain
wild-type (WT) mice. Our workflow has revealed stage-
dependent molecular pathways and kinase activation dynamics
that are disturbed during the initial phase of the amyloid
pathology, providing basic information for understanding how
olfactory molecular networks evolve as the AD pathology
progresses at early stages.
MATERIALS AND METHODS
Human Samples
According to the Spanish Law 14/2007 of Biomedical Research,
informed written consent forms of Brain Bank of IDIBELL,
and Neurological Tissue Bank of IDIBAPS-Hospital Clinic
(Barcelona, Spain) was obtained for research purposes from
relatives of patients included in this study. The study was
conducted in accordance with the Declaration of Helsinki and
all assessments, post-mortem evaluations, and procedures were
previously approved by the Clinical Ethics Committee of Navarra
Health Service. For the validation phase, 14 AD cases were
distributed into different groups according to specific consensus
diagnostic criteria (Braak et al., 2006; Alafuzoff et al., 2008):
initial (Braak I–II), intermediate (Braak III–IV), and advanced
AD stages (Braak V–VI; n = 4–5/group). Five cases from
elderly subjects with no history or histological findings of any
neurological disease were used as a control group. Eighty-five
percentage of human brains considered in this study had a
post-mortem interval (PMI) lower than 15 h (Table 1).
Materials
The following reagents and materials were used. Electrophoresis
reagents were purchased from Bio-rad and Trypsin from
Promega. Antibodies used during the study are summarized
in Table 2.
Animals
Transgenic mice (Tg2576) overexpressing hAPP, carrying
the Swedish (K670N/M671L) familial AD mutation and
under control of the prion promoter (Hsiao et al., 1996),
were used. Mice were on an inbred C57BL/6/SJL genetic
background. The animals were maintained in positive pressure-
ventilated racks at 25 ± 1◦C with a 12 h light/dark
cycle, fed ad libitum with a standard rodent pellet diet
(Global Diet 2014; Harlan Laboratories, Indianapolis, IN,
USA) and had free access to filtered and UV-irradiated
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TABLE 1 | General characteristics of the subjects included in this study.
Case Sex Age PMI (hours) Pathological diagnosis
Controls
BK-0300 F 75 20 ARP I-II
BK-1378 M 78 6 vascular encephalopathy
BK-1078 F 84 6 vascular encephalopathy, NFT I
BK-1195 F 82 8 acute ictus, cerebellar hematoma
BK-1563 M 79 15 acute ictus, AgD II
initial AD
A13/70 F 79 10 AD II/A
A14/29 F 78 3.5 AD II/A
A14/33 M 62 9.5 AD II/0
A14/52 M 70 3 AD II/0
intermediate AD
A12/42 F 82 17 AD IV/A
A12/47 M 81 5 AD III/A
A12/48 M 84 12 AD IV/A
A12/54 M 89 3 AD IV/A
A15/17 M 84 20 AD III/A
Advanced AD
CS-1445 F 73 3.5 AD VI/C + moderate CAA
CS-0662 M 75 4 AD VI/C
CS-0535 F 81 4.5 AD VI/C
CS-0673 M 75 4.25 AD VI/C
CS-1232 M 84 5 AD VI C + CAA
PMI, post-mortem interval; AD/ARP Alzheimer’s disease related pathology;
NFT: neurofibrillary tangles I-VI according to Braak, amyloid plaques A–C according to
CERAD; CAA: cerebral amyloid angiopathy; AgD: argyrophilic grain disease.
TABLE 2 | Antibody used in this study.
Antibodies Product number Distributor
anti-APP 2450 Cell signaling
anti-MEK1/2 9126
anti-phospho-MEK1/2 (S217/221) 9154
anti-ERK1/2 9102
anti-phospho-ERK1/2 (T202/y204) 4370
anti-Akt 4685
anti-phospho-Akt (S473) 4060
anti-p38 MAPK 9212
anti-phospho-p38 MAPK (T180/Y182) 9211
anti-phospho-ATF2 (T71) 5112
anti-SAPK/JNK 9252
anti-phospho-SAPK/JNK (T183/Y185) 9255
anti-SEK1 9152
anti-phospho-SEK1 (S257/T261) 9156
anti-PKA C-alpha 4782
anti-phospho-PKA C (T197) 5661
anti-PP5 2289
anti-PDK1 3062
anti-phospho-PDK1 (S241) 3061
anti-phospho-PKC pan (T514) 9379
anti-phospho-FAK (Y576/577) 3281
anti-Phb1 2426
and anti-Phb2 14085
Anti-PKC-pan SAB4502356 Sigma Aldrich
water. All animal care and experimental procedures were in
accordance with European and Spanish regulations (86/609/CEE;
RD1201/2005) and were approved by the Ethical Committee
of the University of Navarra (no. 018/05). Twenty-four
animals, divided into two sets, were used for proteomics
and transcriptomics analysis (12 mice/approach), with at least
three WT and three Tg2576 transgenic mice per stage (2- and
6-month-old). Additionally, 14- and 18-month-old animals were
used for immunohistochemistry and cell survival routes signaling
analysis. Table 3 summarizes the number and the purpose
for each of the animals. The progressive development of AD
signs in our colony has been previously described (Cuadrado-
Tejedor and García-Osta, 2014). We have previously observed
that behavior (Morris Water Maze test, MWM) is completely
normal and amyloid levels are equal to wild type at 2 months
of age. At 6 months of age, mice show impaired cognitive
functions in the contextual fear conditioning test, coinciding
with the increased cortical and hippocampal soluble β amyloid
(Aβ) levels. At 12 months, the impairment in MWM is present
in most of the mice, but few are normal and with less plaques
(but they are present); and finally, in aged mice (17–18 months),
the pathology is robust and 100% of mice shows plaques and
MWM impairment.
Sample Preparation for Proteomic Analysis
Murine OB specimens were homogenized in lysis buffer
containing 7 M urea, 2 M thiourea, 50 mM DTT. The
homogenates were spinned down at 100,000 × g for 1 h at 15◦C.
Protein concentration was measured in the supernatants with the
Bradford assay kit (Bio-Rad).
Olfactory Bulb Proteomics
Sample preparation, Protein Digestion and Peptide iTRAQ
Labeling were performed as previously described (Zelaya
et al., 2015; Lachén-Montes et al., 2017). Briefly, each
tryptic digest was labeled according to the manufacturer’s
instructions with one isobaric amine-reactive tags as follows:
set 1 (experiment with 2-months-old mice): Tag113, WT-1;
Tag114, WT-2; Tag115, WT-3; Tag116, Tg2576–1; Tag117,
Tg2576–2; Tag118, Tg2576–3, and Set 2 (experiment with 6-
months-old mice): Tag113, WT-1; Tag114, WT-2; Tag115, WT-
3; Tag116, Tg2576–1; Tag117, Tg2576–2; Tag118, Tg2576–3.
After 2 h of incubation, the set of labeled samples were
pooled and evaporated in a vacuum centrifuge. To increase
the proteome coverage, the peptide pool was submitted to
cation exchange chromatography using spin Columns (Pierce).
Twelve fractions were collected (from 5 mM to 250 mM
KCl), concentrated using C18 zip tip solid phase extraction
(Millipore), evaporated under vacuum and reconstituted into
10 µl of 2% acetonitrile, 0.1% formic acid, 98% MilliQ-H20
prior to mass spectrometric analysis. Peptide mixtures were
separated by reverse phase chromatography and analyzed
by mass-spectrometry as previously described (Palomino-
Alonso et al., 2017). The raw MS/MS spectra search were
processed using the MaxQuant software (v.1.5.8.3; Tyanova
et al., 2016a) and searched against the Uniprot proteome
reference for Mus musculus (Proteome ID: UP000000589, May
2017). The parameters used were as follows: initial maximum
precursor (25 ppm), fragment mass deviations (40 ppm);
variable modification (methionine oxidation and N-terminal
acetylation) and fixed modification (MMTS); enzyme (trypsin)
with a maximum of one missed cleavages; minimum peptide
length (seven amino acids); false discovery rate (FDR) for
PSM and protein identification (1%). Frequently observed
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TABLE 3 | Number of animals used in each experimental approach.
Mice Proteomics Transcriptomics Ab burden analysis Signaling routes study
3 month-old wild type 3 3 3 3
3 month-old Tg2576 3 3 3 3
6 month-old wild type 3 3 3 3
6 month-old Tg2576 3 3 3 3
14 month-old wild type − − 3 −
14 month-old Tg2576 − − 3 −
18 month-old wild type − − − 3
18 month-old Tg2576 − − − 3
laboratory contaminants were removed. Protein identification
was considered valid with at least one unique or ‘‘razor’’
peptide. The protein quantification was calculated using at least
two razor + unique peptides, and statistical significance was
calculated by a two-way Student t-test (p < 0.05). A 1.3-fold
change cut-off was used. Proteins with iTRAQ ratios below
the low range (0.77) were considered to be down-regulated,
whereas those above the high range (1.3) were considered
to be upregulated. The Perseus software (version 1.5.6.0;
Tyanova et al., 2016b) was used for statistical analysis and
data visualization. Search results files and MS raw data were
deposited to the ProteomeXchange Consortium1 via the PRIDE
partner repository (Vizcaíno et al., 2014) with the dataset
identifiers PXD007813 (username: reviewer31643@ebi.ac.uk;
password: gMcgfWzD).
Olfactory Bulb Transcriptomics
OB Transcriptomics-Maxwellr 16 simplyRNA Kit (Promega)
was used to extract the OB mRNAs from Tg2576 mice
and WT littermates. The sense cDNA was fragmented and
biotinylated using the Affymetrix Clarion S Pico assay (902932).
Affymetrix mouse Clarion S chips were used according to
the manufacturer protocols. Hybridization, washing, staining,
scanning, and data analysis (Irizarry et al., 2003) were performed
as previously described (Lachen-Montes et al., 2017). As in
other transcriptomic studies performed in AD brains (Silva
et al., 2012; Cuadrado-Tejedor et al., 2016), we worked with a
p-value < 0.01 (without using any method for multiple testing
correction). Microarray data files were submitted to the GEO
(Gene Expression Omnibus) database and are available under
accession number GSE106643.
Bioinformatics
The identification of specifically dysregulated
regulatory/metabolic networks in Tg2576, OBs was analyzed
using QIAGEN’s Ingenuityr Pathway Analysis (IPA; QIAGEN
Redwood City2). The software generates significance values
(p-values) between each biological or molecular event and
the imported molecules based on the Fisher’s exact test
(p ≤ 0.05). The IPA comparison analysis considers the signaling
pathway rank according to the calculated p-value and reports
it hierarchically.
1http://proteomecentral.proteomexchange.org
2www.qiagen.com/ingenuity
Immunoblotting Analysis
Equal amounts of OB protein (5 µg) were resolved in 4%–15%
TGX stain-Free gels (Bio-Rad). OB proteins derived from
murine and human samples were electrophoretically transferred
onto nitrocellulose membranes using a Trans-blot Turbo
transfer system (up to 25V, 7 min; Bio-Rad). Equal loading
of the gels was assessed by stain free digitalization and by
Ponceau staining. Western-blotting was performed as previously
described (Lachén-Montes et al., 2017). After densitometric
analyses (Image Lab Software Version 5.2; Bio-Rad), optical
density values were expressed as arbitrary units and normalized
to total stain in each gel lane.
Immunohistochemistry
Under xylazine/ketamine anesthesia, animals were perfused
transcardially with saline for 3 min at a 11 ml/min flow,
and 4% paraformaldehyde in phosphate buffered saline (PBS)
for 2 min at a 9 ml/min flow. After perfusion, brains
were removed, post-fixed in 4% paraformaldehyde for 1 h
at room temperature and cryoprotected in 30% sucrose
solution in PBS overnight at 4◦C. Brains were sliced into
40-µm-thick coronal sections along the rostral axis with
a freezing microtome (Leica, Germany) and collected in
0.125 M PBS containing 2% dimethylsulphoxide (Sigma),
20% glycerin (Panreac) and 0.05% sodium azide, and stored
at −20◦C until their subsequent analysis. Five free-floating
tissue sections, comprising the OB of four animals per
age group (2-, 6- and 14-month old), were processed for
immunohistochemistry. The sections were washed (3 × 10 min)
with a solution buffer containing PBS 0.125 M (pH 7.4),
0.5% Triton X-100 and 0.1% BSA. After washing, sections
were treated with methanol and H2O2 to inhibit endogenous
peroxidase activity and incubated in 70% formic acid for
5 min to expose the epitope. Subsequently, the sections were
incubated overnight with a primary mouse antibody (6E10)
raised against human Aβ (amino acids 1–16; BioLegend,
San Diego, CA, USA) diluted 1:1,000 in PBS 0.125 M (pH
7.4), 0.5% Triton X-100, 0.1% BSA and 5% normal goat
sera. After washing (3 × 5 min) in PBS, sections were
incubated for 30 min with biotinylated goat anti-mouse
secondary antibody (DakoCytomation, Glostrup, Denmark)
diluted 1:500 in PBS. The sections were then processed
using the avidin–biotin-peroxidase complex (Vectastain kit,
Vector Laboratories, Burlingame, CA, USA) and reacted with
0.05% 3,3′-diaminobenzidine tetrahydrochloride (DAB) and
0.015% H2O2 in 50 mM Tris HCl, pH 7.2. After washing
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in deionized water, sections were mounted on gelatinized
slides, counterstained with Thionine at 60◦C (Panreac Quimica,
Barcelona, Spain) and cover-slipped with DPX (VWR, Dublin,
Ireland). With respect to human OB samples, formalin-
fixed, paraffin-embedded tissue sections from OB (derived
from controls and AD cases) were sectioned at 5 µm and
counterstained with hemeatoxylin for immnuhistochemistry
analysis with anti-SEK1 (ref. 9152; 1:50), anti-phospho-SEK1
(S257/T261; Ref. 9156; 1:250), anti-protein kinase A (PKA)
C-alpha (ref. 4782; 1:50), anti-phospho-PKA C (T197; ref. 5661;
1:250). Visualization was performed by an automated slide
immunostainer (Leica Bond Max) with BondPolymer Refine
Detection (Leica Biosystems Newcastle Ltd., Newcastle upon
Tyne, UK).
RESULTS
APP Overproduction Induces Early, and
Time-Dependent Molecular Derangements
in the Olfactory Bulb of Tg2576 Mice
First, we analyzed the olfactory Aβ pathology in TG2576 mice.
As shown in Figure 1, intraneuronal Aβ immunoreactivity
was observed in 2-month-old transgenic mice, detecting
Aβ deposition in the form of diffuse plaques and mature
plaques at the age of 6 and 14 months, respectively (see
Supplementary Figure S1 for more details). As the primary
aim of our study was to analyze early-onset molecular
derangements in the OB of Tg2576 mice, we deeply monitored
OB molecular disturbances at two time-points (2 and 6 months),
using high-throughput molecular technologies (Figure 2A). At
both time-points, Tg2576 mice displayed abundant full-length
human APP expression in the OB (Figure 2B). To examine
the consequences of initial incremental accumulation of
APP on OB molecular homeostasis, we applied proteomics
and transcriptomics with the final goal to decipher novel
information about the OB site-specific molecular signature at
early AD stages in 2-month and 6-month-old Tg2576 mice.
To analyze the potential differences in olfactory molecular
expression profiles, OB specimens for each experimental group
(Tg2576 and WT mice) were subjected into chemical tags
(iTRAQ) coupled to tandem mass spectrometry and into the
RNA microarray platform. With respect to transcriptome-wide
analysis, 187 protein-coding genes were differentially regulated
in the OB of 2-month-old Tg2576 mice (46 down- and
141 up-regulated genes with respect to WT mice), whereas
287 differentially expressed genes were found in 6-month-
old Tg2576 OBs (107 down- and 180 up-regulated genes
with respect to WT mice; Figure 2B, and Supplementary
Table S1). In the proteomic phase, 1,605 and 1,752 proteins
were quantified at 2 and 6 months, respectively. The expression
levels of 31 proteins were found to be significantly different
between 2-month-old WT and Tg2576 mice (12 down- and
19 up-regulated proteins with respect to WT mice), and
61 differentially expressed proteins were detected at 6 months
of age (26 down- and 35 up-regulated proteins with respect
to WT animals; Figures 2B,C, and Supplementary Table S2).
To partially validate our quantitative LC-MS/MS approach, the
increment in Serine/threonine-protein phosphatase 5 (PP5),
a phosphatase that protects neurons against Aβ toxicity
(Sanchez-Ortiz et al., 2009), was verified by Western-blotting
in 6-month-old Tg2576 OB (Supplementary Figure S2A).
Interestingly, the genes and proteins affected between both stages
varied widely, with only one protein (APP) and nine genes
common to the two time-points (Figure 2D). Of these
nine genes, four were co-downregulated (FOS, ARC, NPAS4,
RGSL1) and five were co-upregulated (STMN4, STMN2, F3,
HIF3a, EMB).
Functional Modules Progressively
Disrupted by Human Mutated APP in the
Olfactory Bulb of Tg2576 Mice
To characterize in detail the proteogenomic modulation
induced by the presence of human mutated APP at pre-plaque
stages in the OB, differential proteomic and transcriptomic
datasets were merged, and functionally analyzed across specific
biological functions (see Supplementary Table S3). Functional
bioinformatic analysis revealed that the accumulation of
APP resulted in disturbances of statistically over-represented
molecular processes directly relevant to adhesion (p-val:
0.0001), viability (p-val: 0.01), and interaction of neuroglia
(p-val: 0.0001), quantity (p-val: 0.003), development (p-val:
0.04), and plasticity of synapse (p-val: 0.001), long-term
potentiation (p-val: 0.006), growth of neurites (p-val: 0.03),
and neuronal proliferation (p-val: 0.04) in 2-month-old
Tg2576 mice (Figure 3). In 6-month-old Tg2576 mice,
the olfactory amyloid pathology predominantly resulted in
the significant alteration of microtubule dynamics (p-val:
0.0001), neuritogenesis (p-val: 0.0005), axonogenesis (p-val:
0.007), synaptic transmission (p-val: 0.01), transmembrane
potential of mitochondria (p-val: 0.00001), metabolism of
ROS (p-val: 0.02), and neurodegeneration of sensory neurons
(p-val: 0.02) between others (Figure 3). However, functional
commonalities focused on synthesis, and concentration of
lipids/fatty acids, cell death, astrocytosis, and accumulation
of vesicles were also detected in 2- and 6-month-old
Tg2576 OBs (Figure 3, and Supplementary Table S3).
Considering that the discovery of unexpected connections
between seemingly unrelated molecules and human mutated
APP is a straightforward approach for the identification
of novel AD causative targets involved in early olfactory
neurodegeneration, we explored whether highly expressed
APP isoform was potentially interconnected with differential
molecular mediators identified in our proteogenomic approach.
For that, functional interactomes were generated using IPA
software. Interestingly, 35 differential functional interactors for
APP were identified in the OB of Tg2576 mice at pre-plaque
stages, suggesting the involvement in related biological functions
(Figure 4). Specifically, at 2 months of age, olfactory APP is
central to an interconnected molecular network composed of
targets with specific subcellular distribution: (i) IGF2, OGN,
TIMP3 at extracellular level; (ii) LRPAP1, NNAT, STMN2 in
the plasma membrane; (iii) cytoplasmic GSTM3, MT-ND3,
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FIGURE 1 | Olfactory β-Amyloid Aβpathology increases with the disease progression in TG2576 mice. Olfactory bulbs (OBs) were harvested from 2-(A–C), 6-(D–F)
and 14-(G–J) month-old Tg2576 mice. Intraneuronal Aβ immunoreactivity can be observed in 2-month-old mice (arrow heads; panel B and more detailed in
panel C). OB samples from 6-month-old animals (panels D–F) shows moderate Aβ deposition in form of diffuse plaques (asterisk). By contrast, mature plaques
(asterisk in panels G,H and insert J) and vascular Aβ (insert I) is evident in 14-month-old Tg2576. Scale bars (500 µm for panels A,D,G, 100 µm for panels B,E,H) or
10 µm (C,F,I,J).
MAPK10, ACTG1, PRDX6, RNF24, NDUFA8, ARC, and
S100B; and (iv) MECP2, FOSB, EGR1, FOS, EGR2 in the
nucleus (Figure 4A). At 6 months of age, the olfactory APP
interactome completely varied at extracellular (MBP, and
CSF1), plasma membrane (GNG2, GAP43, STMN2, MERTK),
cytoplasmic (APBA1, PVALB, MAPK3, GSR, CRYM, MAP2K4,
ABCD3, KLC2, FBXO2, ARC), and nuclear (FOS, TOP2B)
levels (Figure 4B).
Additional integrative networks unveiled an early disruption
of EIF2 signaling based on the up-regulation of a subset
of ribosomal proteins (Figure 5A), suggesting that olfactory
protein synthesis is compromised in 2-month-old Tg2576 mice.
Furthermore, a dysregulation of specific subunits, corresponding
to the mitochondrial complexes I and VI, was evidenced in
the OB of 2-month-old Tg2576 mice, suggesting an olfactory
mitochondrial impairment (Figure 5B). It is well-known
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FIGURE 2 | Dual-omic approach to characterize the OB molecular homeostasis between 2-month-old and 6-month-old Tg2576 mice. (A) An overview of the
experimental workflow used in this study. (B) Differential molecular profiling detected by-omics in Tg2576 OBs (2 and 6 months of age). The OB protein expression
levels of amyloid precursor protein (APP) at early Alzheimer’s disease (AD) stages in Tg2576 mice is shown. (C) Heat maps representing the degree of change for the
differentially expressed proteins (Supplementary Table S2) between 2-and 6-month-old Tg2576 mice respect to wild-type (WT) littermates. Red and green, up- and
down-regulated proteins, respectively. (D) Venn diagram for the differentially expressed genes detected in Tg2576 mice at both time points (Supplementary
Table S1).
that prohibitin complex (constituted by Phb1 and Phb2)
is a mitochondrial inner membrane-bound chaperone that
participates in the mitochondrial respiratory complex assembly,
modulates mitochondrial dynamics, and exerts beneficial effects
on neurons by reducing free radical production (Artal-Sanz and
Tavernarakis, 2009; Zhou et al., 2012). Subsequent experiments
were performed to monitor the expression of both Phb subunits
in the OB from Tg2576 mice. As shown in Figure 5C, a
significant drop in Phb1 levels was evidenced in 2-month-old
Tg2576 OBs, increasing its levels at 6 months of age with
respect to WT littermates. Interestingly, a similar trend was also
observed for the Phb2 protein in Tg2576 mice (Figure 5D).
OB Phb complex was also independently evaluated in WT and
Tg2576 mice during aging. With respect to data obtained at
2 months of age, Phb1 and Phb2 protein levels are decreased
at 6 and 18 months in WT animals, maintaining constant levels
in Tg2576 mice during the aging process (Figures 5C,D). These
data indicate that Phb complex is an early target of human
mutated APP, suggesting that the stable maintenance of Phb
levels may help to counteract the oxidative stress present in
olfactory neurons during AD progression in Tg2576 mice.
Human Mutated APP Modifies the
Olfactory Signaling Routes in a
Stage-Dependent Manner
The molecular network analysis also pointed out functional
links between APP and a cluster of survival kinases, such
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FIGURE 3 | Profiling of molecular biofunctions potentially altered in the OB of Tg2576 mice. Functional analysis was performed with IPA software using exclusively
the database information of experimental and predictive origin regarding central nervous system to be confident about the potential affected signaling pathways (see
Supplementary Table S3 for details).
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FIGURE 4 | Modulation of the APP functional interactome in Tg2576 mice at
the level of OB. Adaptation of APP functional network in Tg2576 OBs at
2 months of age (A) and 6 months of age (B). Relationships between
differential expressed genes/proteins and APP functional interactors are
represented with blue lines. Continuous lines represent direct interactions,
while discontinuous lines correspond to indirect functional interactions.
Up-regulated molecules in red, and down-regulated molecules in green (See
complete legend at: http://qiagen.force.com/KnowledgeBase/
KnowledgeNavigatorPage#).
as ERK, p38 mitogen-activated protein kinase (MAPK), and
Akt (Supplementary Figure S3). Subsequent experiments
were performed to analyze the activation state of MAPKs,
Akt, and p38 MAPK at pre-plaque stages in the OB of
Tg2576 mice. A downstream inactivation in the MAPK pathway
at the level of ERK was specifically observed in 2-month-
old Tg2576 mice (Figure 6B), being the activation state of
upstream MEK unaffected (Figure 6A). Moreover, olfactory
Akt was specifically activated in 6-month-old transgenic
mice (Figure 6C). In addition, Western-blot analysis revealed
an increase in the activation status of OB p38 MAPK
in 2-month-old transgenic mice (Figure 6D). This early
activation was accompanied by a paralleled increment in the
phosphorylation status of ATF2 (Figure 6D), a well-known
downstream substrate of p38 MAPK (Puig et al., 2004). To
complement our signaling mapping, other stress-responsive
kinases were checked. The signal transduction of the SEK1-
stress-activated protein kinase (SAPK) axis was specifically
activated in 6-month-old Tg2576 OBs (Figures 7A,B), while
no appreciable changes were detected in the activation status
of PKA (Figure 7C) and other survival kinases such as
FAK, and PDK1/PKC axis with respect to WT animals
(Supplementary Figure S2).
To deepen our understanding of the APP-dependent
regulatory effects on kinase dynamics during the aging process
in the OB of Tg2576 mice, steady-state levels and phosphorylated
isoforms were independently evaluated in WT and Tg2576 mice
during aging. For that, protein profiles were quantified in a
time-dependent manner at 2-, 6-, and 18-months old (Figure 8).
With respect to data obtained at 2 months of age, the activation
of downstream ERK, and PDK1/PKC axis were constant in
Tg2576 OBs, whereas a drop in the activation status of OB
p38 MAPK was observed in 18-month-old Tg2576 mice when
AD pathology is well established. No changes were observed
in the activation state of olfactory SEK1 during the aging
process in Tg2576 mice, in contrast with the inactivation
observed in 6-, and 18-month-old WT animals (Figure 8).
Conversely, a progressive inactivation was detected in its kinase
downstream cascade as evidenced by SAPK dephosphorylation
in Tg2576 mice (6-, and 18-month old). In addition, a
significant variation was also observed in OB PKA levels in
6-month-old Tg2576.
Olfactory SEK1/MKK4 and PKA Signaling
Are De-regulated Across Human AD
Grading
Much effort has been spent on studying the role of Aβ
in sporadic Alzheimer’s disease (sAD) pathogenesis but the
available information is insufficient to fully understand the
disease progression at the level of olfactory signaling (Lachén-
Montes et al., 2017). To investigate whether SEK1 and PKA
signaling pathways perturbed in the OB of Tg2576 mice
were also associated with human sAD, the activation state
of the corresponding survival pathways was measured by
Western blotting in OBs from sAD subjects with different
neuropathological grading (Table 1). First, we performed
immunohistochemical analysis to localize SEK1 and PKA in
human OB. As shown in Supplementary Figures S4A,B,
positive staining for the activated form of SEK1 was observed
in the OB astrocytes and neurons. However, a specific mild
staining for non-phosphorylated SEK1 was observed in neurons
(Supplementary Figures S4C,D). With respect to an activated
form of PKA, a diffuse staining of neuropil and all OB cellular
components was observed (Supplementary Figures S4E,F), even
in glial cells from granular layer (Supplementary Figure S4F),
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FIGURE 5 | Protein synthesis, and mitochondrial homeostasis are early compromised in Tg2576 at olfactory level. (A) Molecular network representing the
up-regulation of ribosomal proteins (blue circles) in the OB of 2-month-old Tg2576. (B) Molecular network highlighting the dysregulation of specific components of
the mitochondrial respiratory chain (Complex I, and Complex VI subunits) in the OB of 2-month-old Tg2576. (C) Time-dependent disruption of the olfactory Phb1 in
Tg2576 mice. Phb expression was monitored by Western-blotting. (D) Time-dependent disruption of the olfactory Phb2 in Tg2576 mice. Phb expression was
monitored by Western-blotting. Equal loading of the gels was assessed by stain-free digitalization. Panels show histograms of band densities. Data are presented as
mean ± standard error of the mean (SEM) from three independent OB samples per group (∗P < 0.05 vs. control group; ∗∗P < 0.01 vs. control group). Right graphs
represent the expression of both Phb subunits during the aging process in WT and Tg2576 mice (2-, 6-, and 18-month-old).
while a mild staining in neuropil was observed for the
non-phosphorylated PKA (Supplementary Figures S4G,H). As
shown in Figure 9, the activation of SEK1 was specifically
increased in advanced AD stages (Braak V–VI; Figure 9A).
However, PKA activity was significantly increased in the initial
(Braak I–II) AD stage, with respect to subjects with normal
neuropathological examination (Figure 9B). In intermediate AD
stage (Braak III–IV), a significant increment was also observed in
total and activated PKA levels (Figure 9B).
DISCUSSION
We consider that a better understanding of the molecular
events affected by the progressive accumulation of amyloid
pathology might offer new olfactory targets for earlier diagnosis
and therapeutic intervention. In particular, we report that:
(i) multiple OB proteotranscriptomic variations appear at
pre-plaque stages in Tg2576 mice; (ii) the functional interactome
of the hAPPSw isoform at olfactory level is progressively
modulated in these mice; (iii) the mitochondrial PHB
complex was compromised at early stages in Tg2576 OBs;
(iv) specific olfactory signaling routes (Akt, p38 MAPK, SEK1,
and SAPK) were modulated in a time-dependent manner
respect to WT animals; (v) APP overproduction induced
specific regulatory effects on kinase dynamics (SEK1/SAPK,
PKA) during the aging process in Tg2576 mice; and (vi) the
SEK1 and PKA pathways were differentially activated during
human AD grading at the level of the OB. All these findings
at the very early pre-plaque stage provided mechanistic clues
on the olfactory mechanisms involved in the progression
of cognitive deficits previously reported in these mice
(Cuadrado-Tejedor and García-Osta, 2014).
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FIGURE 6 | APP overproduction affects the activation state of olfactory ERK1/2, Akt, and p38 mitogen-activated protein kinase (MAPK) at early AD stages in
Tg2576 mice. Levels and residue-specific phosphorylation of MEK1/2 (A), ERK1/2 (B), Akt (C), and p38 MAPK-ATF2 axis (D). Equal loading of the gels was
assessed by stain-free digitalization. Panels show histograms of band densities. Data are presented as mean ± SEM from three independent OB samples per group.
∗P < 0.05 vs. control group; ∗∗P < 0.01 vs. control group.
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FIGURE 7 | APP overproduction specifically modulates the activation of the SEK1/MKK4-stress-activated protein kinase (SAPK)/JNK axis in 6-month-old
Tg2576 mice. Time-dependent expression of total and phosphorylated levels of SEK1 (A), SAPK/JNK (B), and protein kinase A (PKA; C). Equal loading of the gels
was assessed by stain-free digitalization. Panels show histograms of band densities. Data are presented as mean ± SEM from three independent OB samples per
group. ∗P < 0.05 vs. control group.
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FIGURE 8 | Monitorization of survival kinases during the aging process in WT and Tg2576 OBs. Western-blotting were performed for the kinase panel (total and
phosphorylated levels) in the OB from WT and Tg2576 mice of 2, 6, and 18 months of age. Quantitation data were referred to the observed levels in 2-month-old
mice for each condition. ∗P < 0.05 vs. 2-month-old mice; ∗∗P < 0.01 vs. 2-month-old mice.
To systematically assess the global effect of olfactory APP
production on gene expression at the transcript and protein level,
we used a combinatorial omics analysis. The minimal overlap
observed in transcriptome and proteome remodelings between
2-, and 6-month-old Tg2576 mice support the hypothesis that
distinctive pathophysiological processes are involved in the OB
during the initial progression of AD-like amyloid pathology.
For example, functional clustering suggested that changes in
the growth of neurites (in 2-month-old transgenic mice), and
microtubule dynamics in the OB (in 6-month-old Tg2576 mice)
occur in the absence of neuropathological amyloid plaques,
supporting the notion that cytoskeletal remodeling is an early
AD pathological hallmark (Do Carmo et al., 2018). Despite the
experimental and technical noise in both mRNA and protein
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FIGURE 9 | Olfactory SEK1/MKK4 and PKA are differentially activated across Braak stages in human AD. Levels and residue-specific phosphorylation of
SEK1/MKK4 (A), and PKA (B) in the OB across AD phenotypes. Equal loading of the gels was assessed by Ponceau staining and hybridization with a GAPDH
specific antibody. Right panels show histograms of band densities. Data are presented as mean ± SEM from five independent OB samples per group. ∗P < 0.05 vs.
control group; ∗∗∗P < 0.001 vs. control group. Representative Western blot gels are shown.
measurements, which may contribute to an underestimation
of true correlations, RNA-protein correlation was missing
in our study. Buffering of mRNA variation against protein
levels can occur at multiple levels, including intra- and inter-
individual genomic variation (Battle et al., 2015; Liu et al.,
2016). The discrepancy we observed may be due to: (i) the
use of different set of animals for each technological platform;
(ii) the spatial and temporal delayed synthesis between mRNA
and protein (Liu et al., 2016); (iii) post-transcriptional events;
and (iv) the different hydrophobicity and solubility of specific
proteome subsets (e.g., olfactory receptors), which hampers their
characterization and quantitation by mass-spectrometry.
Prohibitin deficiencies have been previously associated with
neurodegenerative phenotypes (Merkwirth et al., 2012; Dutta
et al., 2018). During aging, our data indicated that Phb levels
are stable while mutated APP is overproduced, probably to
counteract the disease-aggravating oxidative stress during AD
progression in Tg2576 mice. Generally, repression/induction
of Phb1 is paralleled by a concomitant decrease/increase
of its assembly partner Phb2 (Sánchez-Quiles et al., 2010;
Merkwirth et al., 2012). Accordingly, OB Phb subunits are
functionally interdependent in Tg2576 mice. In contrast,
Phb subunits are not interdependent in the OB during AD
neurodegeneration in humans (Lachén-Montes et al., 2017),
indicating that the tangled regulatory mechanisms that govern
the mitochondrial homeostasis in olfactory cells significantly
differ between transgenic mice and sporadic human AD.
Aberrant regulation of a subset of kinases may represent
the triggering events leading to the spread of a perturbed
signaling in AD (Perluigi et al., 2016). p38 MAPK is a
multifunctional kinase that is activated by Aβ in cultured
neurons (Criscuolo et al., 2015), phosphorylates Tau protein (Li
et al., 2003; Ferrer et al., 2005), and mediates the Aβ-induced
inflammatory activation (Bachstetter et al., 2011). Different
alterations of p38 MAPK pathway have been observed in the
OB, hippocampus, and cortical areas at early stages in human
AD (Hensley et al., 1999; Sun et al., 2003; Munoz and Ammit,
2010; Criscuolo et al., 2015). In Tg2576 mice, we observed an
early activation of p38 MAPK (validated by paralleled increase
in ATF2 phosphorylation levels), suggesting detrimental effects,
such as neuroinflammation and excitotoxicity at the level of the
OB (Yi et al., 2018). Although Akt has been recently proposed
as a therapeutic target for AD-associated memory impairments
(Griffin et al., 2005), different results have been obtained about
the Akt activation across brain structures of human AD (Rickle
et al., 2004; Petersen et al., 2007; Lachén-Montes et al., 2016).
The specific activation of olfactory Akt observed in 6-month-old
Tg2576 mice indicates potential protective mechanisms against
memory impairments and synaptic deficits (Griffin et al., 2005).
In an effort to delineate the oxidative stress signaling events
in the OB of Tg2576 mice, we observed an increment in the
activation of SAPK/JNK pathway in 6-month-old Tg2576 OBs.
This activation precedes the Aβ deposition, although Aβ may
enhance its activation at a later time (Zhu et al., 2001). In the
human brain, phospho-SAPK is significantly increased in AD
over control cases, overlapping with Tau-positive neurofibrillary
pathology (Bachstetter et al., 2011; Kelly, 2018). In this study, we
have detected an increment in the expression of phosphorylated
SEK1 (an upstream activator of the SAPK/JNK route) exclusively
in subjects with advanced AD stage (Braak V–VI). Previous
reports suggest that this activation may play a role in the tau
phosphorylation, and consequently, the formation of NFTs in
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late AD stages (Zhu et al., 2001). PKA is a tau-kinase and
its expression/activity tends to be reduced in different contexts
of AD pathology (Liang et al., 2007). In humans, a decrease
in PKA activity was observed in the temporal cortex from
AD subjects with a Braak stage V–VI (Iulita et al., 2014).
However, we report a PKA overactivation that occurs in the
OB derived from AD subjects with initial stages (Braak I–II),
indicating that cAMP signaling appears to be stage and brain
region specific.
Although our study has uncovered many intricacies in
OB molecular homeostasis during early stages of AD-related
amyloidogenic pathology, there are potential limitations of our
study that warrant discussion. First, due to technological issues,
we failed to accurately quantify many proteins expressed at
low levels that might also participate in the olfactory AD
progression in Tg2576 mice. Second, our results are limited
by transcript/protein abundance averaging among the multiple
cell layers present in the OB, hampering the exploration of
olfactory cell-type specific molecular alterations. Third, Aβ, APP,
and its derived species may co-exist inside neurons (Crowe
et al., 2018), and based on our experimental workflow, we
cannot pinpoint which APP-derived species are responsible for
the observed molecular disturbances. Finally, this study should
be complemented with behavior testing to characterize which
molecular abnormalities are directly linked to the cognitive
deficit, as well as additional omic studies performed in different
brain areas to verify the specificity of the molecular alterations
detected at the level of the OB.
CONCLUSION
Our dual-omic approach revealed the disruption of multiple
molecular pathways at early stages of the OB amyloid pathology,
leading to the identification of differential olfactory targets linked
to APP metabolism. These findings point out the potential
utility of alternative olfactory pathways for disease modification,
in a stage-dependent manner, through intranasal therapies
(Cheng et al., 2017) based on enzyme replacement or specific
drug delivery (Agrawal et al., 2018).
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FIGURE S1 | Olfactory β-Amyloid pathology increases with the disease
progression in TG2576 mice. OBs were harvested from 2 (A–C), 6 (D–F) and
14 (G–J) month-old Tg2576 mice. Intraneuronal Aβ immunoreactivity can be
observed in 2 month-old mice (arrow heads; panel B and more detailed in
panel C). OB samples from 6 month-old animals (panels D,E and F) shows
moderate Aβ deposition in form of diffuse plaques (asterisk). By contrast, mature
plaques (asterisk in panel G, H and insert J) and vascular Aβ (insert I) is evident in
14 month-old Tg2576. Scale bars 500 µm for panels A, D, G, 100 µm for
panels B, E, H or 10 µm (C, F, I, J). (GL: glomerular layer; EPL: external plexiform
layer; MC: mitral layer; GrL: granular layer; AON: anterior olfactory nucleus).
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FIGURE S2 | OB PP5 up-regulation in 6-month-old Tg2576 mice (∗∗P < 0.01
respect to control group) (A). No significant changes were found in FAK and
PDK1/PKC signaling axis (B).
FIGURE S3 | Visualization of predictive interactions between APP and survival
kinases (orange circles) based on differential datasets derived from 2-month-old
Tg2576 mice.
FIGURE S4 | Immunohistochemical localization of OB SEK1 and PKA
(phosphorylated and non-phosphorylated forms). Representative
immunohistochemical staining pattern of pSEK1 (A,B), SEK1 (C,D), pPKA (E,F)
and PKA (G,H) in control and AD cases.
TABLE S1 | Differential OB transcriptome in 2- and 6-month-old Tg2576 mice
respect to WT mice.
TABLE S2 | Diffefrential OB proteome in 2- and 6-month-old Th2576 mice
respect to WT mice.
TABLE S3 | Functional analysis of omics datasets.
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